(3.238.96.184) 您好!臺灣時間:2021/05/08 04:40
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

: 
twitterline
研究生:沈惠娟
研究生(外文):Hui-Chuan Shen
論文名稱:利用母血唐氏症篩檢四指標預測妊娠糖尿病
論文名稱(外文):Predictive Value of Four Indicators Included in Maternal Serum Down Syndrome Screening for Gestational Diabetes Mellitus
指導教授:陳勝咸
指導教授(外文):Sheng-Hsian Chen
學位類別:碩士
校院名稱:南台科技大學
系所名稱:生物科技系
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
畢業學年度:101
語文別:中文
論文頁數:37
中文關鍵詞:妊娠糖尿病唐氏症口服葡萄糖耐性試驗唐氏症四指標篩檢
外文關鍵詞:Gestational diabetes mellitusDown’s syndromeDown’s syndrome quadruple testoral glucose tolerance test
相關次數:
  • 被引用被引用:1
  • 點閱點閱:503
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:85
  • 收藏至我的研究室書目清單書目收藏:11
妊娠糖尿病是懷孕期間常見的併發症,而持續增高卻控制不佳的高血糖對產婦與胎兒都會產生併發症造成危險,先前文獻指出妊娠糖尿病的發生與激素分泌造成胰島素抗性,有強烈關聯性存在,尤其是胎兒-胎盤單位所分泌的懷孕相關荷爾蒙;然而妊娠糖尿病的檢測必需等到懷孕第24-28週進行,因為至今尚未有明確的指標在懷孕初期即可預知妊娠糖尿病的發生。因此我們利用在妊娠中期15-20+6 週進行的唐氏症母血四指標篩檢,分別是AFP、total hCG 、uE3及inhibin-A,期望能更早預測妊娠糖尿病的發生。本篇研究選自奇美醫學中心2009年8月起至2012年07月到院產檢孕婦4293人次中,以隨機選出正常妊娠者117位為對照組,口服葡萄糖耐性試驗正常者110位、口服葡萄糖耐性試驗一筆異常者38位,確診為妊娠糖尿病者60位,探討四指標在不同程度的血糖不耐及妊娠糖尿病發生的相關聯性。妊娠糖尿病的確認依據美國糖尿病學會(ADA, 2009)的100 g口服葡萄糖耐性試驗的診斷標準。統計結果顯示妊娠糖尿病盛行率約為4.05%,妊娠糖尿病組其體重與年齡皆較其他組別為高(體重 p=0.000,年齡 p=0.036),高唐氏症危險率者比正常者罹患妊娠糖尿病的比例也較高(5.9%: 2.4%;p=0.005),而四指標中僅有uE3具有統計上的顯著差異 (uE3: 0.93 MoM , 95%CI : 0.87-0.99 ; control: 1.02 MoM , 95%CI : 0.97-1.06; p=0.022),ROC的曲線下面積(AUC)為0.612 ( p=0.015)。由我們的結果顯示,唐氏症危險率偏高者罹患妊娠糖尿病的比例比危險率正常者為高;在妊娠中期進行的唐氏症母四指標篩檢中的uE3,其濃度偏低時與妊娠糖尿病的發生最具有關聯性,可預測併發妊娠糖尿病的發生。
Gestational diabetes mellitus(GDM) is a common complication that may occur during pregnancy. Continuously rising and poorly controlled hyperglycemia can endanger both mother and fetus because of adverse pregnancy outcome. Previous studies have shown that GDM is strongly correlated to insulin resistance that is induced by hormone secretions, particularly pregnancy-associated hormones relevant to the fetal-placental unit (FPU). However, GDM cannot be diagnosed until 24-28 weeks of gestation because specific markers are unavailable for predicting the development of GDM during the first trimester. This study used Down’s syndrome screening that are during the second trimester using quadruple test (ie, AFP, total hCG, uE3, and inhibin-A) to facilitate the early prediction of GDM. The research participants were randomly selected from 4293 pregnant women who received prenatal examinations in Chi-Mei Medical Center between August 2009 and July 2012. In this study, 117 healthy pregnant women were included into the control group; 110 participants were within all normal glucose range on the oral glucose tolerance test (OGTT); 38 women received one abnormal result on the OGTT; and 60 were confirmed to have GDM. This study explores the correlation of the quad markers to varying glucose intolerance levels and the development of GDM. GDM was confirmed based on the diagnostic criteria for the 100-g OGTT established by the American Diabetes Association (ADA, 2009). The statistical results showed that the prevalence of GDM was 4.05%. The group with GDM all demonstrated heavier weights and older ages compared to other groups (weight: P = 0.000; age: P =0 .036). Pregnant women at high risk of Down’s syndrome had a higher GDM incidence rate compared to healthy pregnant women (5.9%:2.4%;p=0.005). Only uE3 among the quad markers presented statistically significant differences (uE3: 0.93 MoM, 95% CI: 0.87-0.99; control: 1.02 MoM, 95% CI: 0.97-1.0; P =0 .022). The area under the receiver operating characteristic (ROC) curve was 0.612 (P =0.015). The results indicated that pregnant women at high risk for Down’s syndrome tended to have a higher incidence rate of GDM compared to pregnant women with normal risks. In the second trimester screening for Down’s syndrome using the quad markers, uE3 in a low concentration can to prediction the development of GDM.
目次
中文摘要 i
英文摘要 ii
誌謝 iv
目次 vi
表目錄 vii
圖目錄 viii
縮寫對照表 ix
第一章 緒論 1
1.1 妊娠糖尿病(Gestational Diabetes Mellitus) 1
1.1.1妊娠糖尿病的發生 2
1.1.2妊娠性糖尿病的診斷 3
1.2 唐氏症 (Down syndrome) 5
1.2.1母血唐氏症篩檢 (Maternal Serum Down syndrome screening) 5
1.3 文獻回顧 7
第二章 研究動機與目的 9
第三章 材料與方法 10
3.1 研究流程設計與分組 10
3.2 研究對象來源 11
3.3 研究資料來源 11
3.4 統計分析 11
第四章 實驗結果 12
4.1 研究族群分析 12
4.2 妊娠糖尿病盛行率 13
4.3 高唐氏症篩檢危險率與罹患妊娠糖尿病的比例 13
4.4 唐氏症四指標與罹患妊娠糖尿病的相關性 13
第五章 討論 15
5.1 妊娠糖尿病與年齡、體重的相關性 15
5.2 妊娠糖尿病盛行率 15
5.3唐氏症篩檢危險率與併發妊娠糖尿病的探討 16
5.4 uE3與罹患妊娠糖尿病的相關性 16
5.5 研究限制 17
第六章 結論 18
第七章 參考文獻 28
附錄 35
丁芳(1995)。耐糖不良與妊娠糖尿病孕婦與新生兒週產期併發症之研究。國立陽明醫學大學,未出版碩士論文,台北,台灣。
林明泉(1997)。第三十四章 胎兒發育異常篩檢,714頁,林明泉著,臨床血清免疫學。合記圖書出版社,台北。
黃奕燦、林瑞祥、楊應欽、李裕祥、祝春紅、江千代(1998)•妊娠糖尿病產後追蹤之意義•台灣醫界,41,10-13。
Ahmed SA, Shalayel MH. Role of cortisol in the deterioration of glucose tolerance in Sudanese pregnant women. East Afr Med J 1999; 76: 465-467
American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 2009; 32(Suppl. 1): S62–S67
American Diabetes Association. Executive Summary: Standards of Medical
Care in Diabetes-2011. Diabetes Care 2011; 34(Suppl. 1): S54–S60
Aymé S, Aurran Y, Chabal F, Gombert A, Loundou H, Montfort C, Sollier M, Silvestri A. Evaluation of trisomy 21 risk by serial determination of chorionic gonadotrophin hormone and alpha-fetoprotein: results of a national pilot study. Contracept Fertil Sex 1993 ; 21: 133-143
Barbour LA, Shao J, Qiao L, et al. Human placental growth hormone causes severe insulin resistance in transgenic mice. Am J Obstet Gynecol 2002; 186: 512–517.
Beneventi F, Simonetta M, Lovati E, Albonico G, Tinelli C, Locatelli E,
et al. First trimester pregnancy-associated plasma protein-A in pregnancies
complicated by subsequent gestational diabetes. Prenat Diagn 2011; 31: 523–526
Bogart, M.H., Pandian, M.R., Jones, O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987; 7: 623-630
Buchanan TA, Xiang AH. Gestational diabetes mellitus. J. Clin Invest 2005; 115: 485-491
Caliskan E, Kayikcioglu F, Ozt€urk N, Koc S, Haberal A. A population-based risk
factor scoring will decrease unnecessary testing for the diagnosis of gestational
diabetes mellitus. Acta Obstet Gynecol Scand 2004;83:524–530
Canick, J.,Knight,G.J.,Polomaki, G.E. et al. Low second trimester maternal serum unconjugated estriol in pregnancies with Down’s syndrome. Br J obstet Gynecol 1988; 297: 883-887
Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144: 768–773
Carr DB, and Gabbe S. Gestational Diabetes: Detection, Management, and Implications. Clinical diabetes 1998; 16: 5-19
Cheung N, Wasmer G, Al-Ali J. Risk factors for gestational diabetes among Asian women. Diabetes Care 2001; 24 : 955-956
Dornhorst A, Paterson CM, Nicholls JS, Wadsworth J, Chiu DC, Elkeles RS, Johnston DG, Beard RW. High prevalence of gestational diabetes in women from ethnic minority groups. Diabet Med 1992; 9: 820–825
Down JLH. Observation on an ethic classification on idios. Clinical Lecture Report, London Hospital 1866; 3: 259
Hornns PJ. On the decrease of glucose tolerance in pregnancy. A review. Diabet
Metab 1985; 11: 310-315
Hu XY, Bian XM, Jiang YL, Liu SY. Relationship of adverse pregnancy outcomes and
a high risk serum screen for Down syndrome in the second trimester. Zhonghua Fu Chan Ke Za Zhi. 2012 ;47:427-30.
International Association of the Diabetes and Pregnancy Study Groups. Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care 2010; 33: 676–682
Isouard G (1979) Measurement of serum levels of oestriol and human placental
lactogen in the management of preeclamptic pregnancies. Med J Aust 2:401–404
Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes
mellitus: results from a survey of country prevalence and practices. J Matern Fetal
Neonatal Med 2012;25:600–610
Khoshnniat Nikoo M , Abbaszadeh Ahranjani S, Larijani B. A review on the prevalence of gestational diabetes mellitus (GDM) in different regions of Iran. Iranian Journal of Diabetes and Lipid Disorders 2009; 47-56
Kim SY, Kim SK, Lee JS, Kim IK, Lee K . The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down’s syndrome. Yonsei Med J 2000; 41:226–229
Kjos SL, Peters RK, Xiang A, Henry OA, Montoro MN, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 1995; 44: 586–591
Klieger C, Pollex E, Kazmin A, et al. Hypoglycemics: pharmacokinetic considerations during pregnancy. Ther Drug Monit 2009; 31: 533-541
Kowalczyk TD, Cabaniss ML, Cusmano L Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998;91:396–400
Kuhl C. Aetiology of gestational diabetes. Baillieres Clin Obstet Gynaecol 1991; 5: 279–292
Lejeune J, Gautier M, Turpin R. Etude des chromosomes somatiques de neu enfants mongoliens. CR Acad Sci Paris 1959; 248: 1721-1722
Macintosh MC, Iles R, Teisner B, Sharma K, Chard T, Grudzinskas JG, Ward RH, Muller F. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks. Prenat Diagn 1994 ; 14: 203-208
Metzger BE, Cho NH, Roston SM, Rodvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. Diabetes Care 1993; 16: 1598–1605
Metzger BE, Coustan DR. Summary and recommendations of the Fourth International
Workshop-Conference on Gestational Diabetes Mellitus: the organizing committee. Diabetes Care 1998; 21(Suppl. 2): B161–B167
Michael D. Berkus, Oded Langer, Berkus Michael D., Langer Oded. Glucose Tolerance Test Periodicity: The Effect of Glucose Loading.Obstetrics and Gynecology 1995; 85: 423-427
Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687–694
Narchi H, Kulaylat N. High incidence of Down's syndrome in infants of diabetic mothers. Arch Dis Child.1997 ;77:242-244.
Naylor CD, Sermer M, Chen E, Farine D.Toronto Trihospital Gestational Diabetes
Project Investigators. Selective screening for gestational diabetes mellitus. N Engl J
Med 1997;337:1591–1596
Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000; 107: 1265–1270
Pedersen JF, Sørensen S, Mølsted-Pedersen L. Serum levels of human placental lactogen, pregnancy-associated plasma protein A and endometrial secretory protein PP14 in first trimester of diabetic pregnancy. Acta Obstet Gynecol Scand 1998; 77: 155–158
Peled.Y, Gilboa.Y, Perri.T et al. Strict glycemic control in diabetic pregnancy-implications for second-trimester screening for Down syndrome. Prenat Diagn 2003; 23: 888–890
Penrose LS. The relative effects of paternal and maternal age in mongolism. J Genet 2009; 88: 9-14
Polderman KH, Gooren LJ, Asscheman H, et al. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Meta 1994; 79: 265–271
R¨aty R., Anttila L., Virtanen A., Koskinen P. et al. Maternal midtrimester free β-HCG and AFP serum levels in spontaneous singleton pregnancies complicated by gestational diabetes mellitus, pregnancy-induced hypertension or obstetric cholestasis. Prenat Diagn 2003; 23: 1045–1048
Rieck S, Kaestner KH. Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab 2010; 21: 151-158
Ryan EA and Enns L. Role of Gestational Hormones in the Induction of Insulin Resistance. J Clin Endocrinol Metab 1988; 67: 341-347
Shirazian N, Emdadi R, Mahboubi M, et al. Screening for gestational diabetes:
usefulness of clinical risk factors. Arch Gynecol Obstet 2009;280:933–937
Spencer K, Cowans NJ, Spencer CE, Achillea N. A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 2010; 30: 937–940
Sweeney AT, Brown FM. Gestational diabetes mellitus. Clinics in Laboratory
Medicine 2001; 21: 173-192
Teede HJ, Harrison CL, Teh WT, Paul E, Allan CA. Gestational diabetes: development
of an early risk prediction tool to facilitate opportunities for prevention. Aust N Z JObstet Gynaecol 2011;51:499-504
Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K. Firsttrimester prediction of gestational diabetes mellitus: examining the potential of
combining maternal characteristics and laboratory measures. Diabetes 2010;59:
3017–3022
Say N C An , Ahmet N. , Arda S. •,Varol F.G. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns .Archives of Gynecology and Obstetrics . 2008 ;277:47-53
Tran TS, Hirst JE, Do MA, Morris JM, Jeffery HE. Early prediction of gestational diabetes mellitus in Vietnam: clinical impact of currently recommended diagnostic criteria. Diabetes Care.2013 ;36:618-624
Valenti C, Schutta EJ, Kehaty T. Prenatal diagnosis of Down’s syndrome. Lancet II 1968; 220
Wald NJ, Densem, J.W., George, L., Muttukrishna, S.et al. Prenatal screening for Down’s syndrome using inhibin-A as a serum marker. Prenat.Diagn 1996; 16: 143-153
Wald NJ, Kennard A, Hackshaw AK. First trimester serum screening for Down's syndrome. Prenat Diagn 1995 ; 15: 1227-1240
Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181-246
Huttly W, Rudnicka A, Nicholas J. Wald. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 2004; 24: 804–807
Wu, R. C., Kuo, P. L., Chen, C. P., Yao, B. L., Chang, F. M., & Liu, C. H., et al. The cut-off value of 50gm oral glucose screening test (GST) in pregnant Chinese women. Advences in Obstetrics and Perinatology 1992; 3: 76-80
Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP et al Second-trimester maternal serum marker screening: maternal serum -fetoprotein, -human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181:968–974
連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊
 
1. Part I:藉由蛋白質體分析黃蓮素誘導乳癌細胞中之毒殺性機制 Part II:糖尿病 II-I:利用蛋白質體找出第一型糖尿病血漿生物標誌分子:發現 hemopexin為第一型糖尿病患者腎病血漿中新穎性生物標誌分子 II- II:藉由蛋白質體找出第二型糖尿病患者腎病血漿中生物標誌分子
2. 第二孕期一般及妊娠糖尿病孕婦之生活品質探討
3. 台灣母血唐氏症篩檢對唐氏症出生趨勢之影響
4. 耐糖不良與妊娠糖尿病孕婦與新生兒週產期併發症之研究
5. 台灣母血唐氏症篩檢對唐氏症出生趨勢之影響
6. 糖尿病患性功能障礙與糖尿病控制之相關探討
7. 探究妊娠糖尿病婦女懷孕歷程的生活經驗
8. 糖尿病前期發生率之估算與糖尿病篩檢工具預測糖尿病前期發生的評估
9. 發展理論模式以預測妊娠糖尿病發
10. 台灣地區妊娠糖尿病母親其新生兒與先天性缺陷之相關
11. 醫學營養治療於妊娠糖尿病婦女對其胎兒臍帶血中內皮前趨細胞之數目及活性的影響
12. 探討老人憂鬱與糖尿病風險之關聯並預測新生糖尿病之風險
13. 初次接受產前母血唐氏症篩檢陽性反應婦女之懷孕生產經驗
14. 影響懷孕婦女對不同唐氏症篩檢選擇的因素與後續遺傳諮詢需求
15. 以非肥胖型基因轉殖糖尿病小鼠模式探討protein tyrosine phosphastase non-receptor type 22 (Ptpn22) 對作用型及調節型T細胞差異性調控之機制及其對自體免疫糖尿病之影響
 
系統版面圖檔 系統版面圖檔